Close Menu

NEW YORK – The Office of Biomedical Advanced Research and Development Authority (BARDA) is now seeking applications from diagnostics makers to support the development of tests for novel coronavirus 2019-nCoV.

On Tuesday, under the auspices of its Division of Research, Innovation & Ventures (DRIVe), BARDA launched an Easy Broad Agency Announcement, or EZ-BAA, funding solicitation that is specifically for diagnostics, enabling diagnostics developers to submit assays for funding.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.